Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA
Authors:
- Era-Edta CouncilECEra-Edta Council
- Alberto OrtizAOAlberto Ortiz
- Mario CozzolinoMario Cozzolino
- Danilo FliserDFDanilo Fliser
- Denis FouqueDFDenis Fouque
- Dimitrios GoumenosDGDimitrios Goumenos
- Ziad A MassyZMZiad A Massy
- Alexander R RosenkranzARAlexander R Rosenkranz
- Ivan RychlıkIRIvan Rychlık
- Maria Jose SolerMSMaria Jose Soler
- Kate StevensKSKate Stevens
- Roser TorraRTRoser Torra
Top Cited Papers
Open Access
- 19 December 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 36 (1) , 87-94
Abstract
Diabetes, hypertension and cardiovascular disease have been listed as risk factors for severe coronavirus disease 2019 (COVID-19) since the first report of the disease in January 2020. However, this report did not mention chronic kidney disease (CKD) nor did it provide information on the relevance of estimated glomerular filtration rate (eGFR) or albuminuria. As the disease spread across the globe, information on larger populations with greater granularity on risk factors emerged. The recently published OpenSAFELY project analysed factors associated with COVID-19 death in 17 million patients. The picture that arose differs significantly from initial reports. For example, hypertension is not an independent risk factor for COVID-19 death [adjusted hazard ratio (aHR) 0.89], but renal disease very much is. Dialysis (aHR 3.69), organ transplantation (aHR 3.53) and CKD (aHR 2.52 for patients with eGFR 2) represent three of the four comorbidities associated with the highest mortality risk from COVID-19. The risk associated with CKD Stages 4 and 5 is higher than the risk associated with diabetes mellitus (aHR range 1.31–1.95, depending upon glycaemic control) or chronic heart disease (aHR 1.17). In another recent publication, the Global Burden of Disease collaboration identified that worldwide, CKD is the most prevalent risk factor for severe COVID-19. Moreover, the distribution of risk factors for COVID-19 mortality appears to be different in patients with CKD when compared with the general population. The high prevalence of CKD in combination with the elevated risk of mortality from COVID-19 in CKD necessitates urgent action for this group of patients. This article defines essential action points (summarized in Box 1), among which is advocating the inclusion of CKD patients in clinical trials testing the efficacy of drugs and vaccines to prevent severe COVID-19.Keywords
Funding Information
- ERA-EDTA
- Dutch Kidney Foundation
This publication has 24 references indexed in Scilit:
- Covid-19 and long term conditions: what if you have cancer, diabetes, or chronic kidney disease?BMJ, 2020
- A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseasesNephrology Dialysis Transplantation, 2019
- Children of a lesser god: exclusion of chronic kidney disease patients from clinical trialsNephrology Dialysis Transplantation, 2019
- Clarifying the concept of chronic kidney disease for non-nephrologistsClinical Kidney Journal, 2019
- Vaccination in Chronic Kidney DiseaseAdvances in Chronic Kidney Disease, 2019
- The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problemNefrología, 2019
- Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territoriesThe Lancet, 2018
- Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failureThe Lancet, 2014
- GBD 2010: a multi-investigator collaboration for global comparative descriptive epidemiologyThe Lancet, 2012
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialThe Lancet, 2011